| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Platelet Activation | 57 | 2024 | 643 | 9.160 |
Why?
|
| Blood Platelets | 81 | 2024 | 2464 | 8.850 |
Why?
|
| Platelet Function Tests | 27 | 2024 | 275 | 3.380 |
Why?
|
| Platelet Aggregation | 32 | 2022 | 769 | 3.360 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 11 | 2018 | 285 | 3.190 |
Why?
|
| Platelet Aggregation Inhibitors | 39 | 2021 | 2764 | 3.170 |
Why?
|
| Flow Cytometry | 32 | 2024 | 5891 | 2.480 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 24 | 2021 | 577 | 2.450 |
Why?
|
| Blood Platelet Disorders | 7 | 2024 | 60 | 2.300 |
Why?
|
| Ticlopidine | 19 | 2018 | 729 | 2.270 |
Why?
|
| Receptors, Purinergic P2Y12 | 12 | 2018 | 117 | 2.160 |
Why?
|
| Dinucleoside Phosphates | 6 | 2018 | 71 | 2.070 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 7 | 2024 | 144 | 1.920 |
Why?
|
| Adenosine Diphosphate | 18 | 2016 | 421 | 1.890 |
Why?
|
| P-Selectin | 20 | 2021 | 598 | 1.830 |
Why?
|
| Receptors, Purinergic P2Y1 | 7 | 2018 | 40 | 1.780 |
Why?
|
| Platelet-Rich Plasma | 6 | 2021 | 180 | 1.660 |
Why?
|
| Hemostasis | 7 | 2024 | 467 | 1.580 |
Why?
|
| Thiophenes | 12 | 2018 | 570 | 1.550 |
Why?
|
| Purinergic P2 Receptor Antagonists | 5 | 2013 | 67 | 1.380 |
Why?
|
| Receptor, PAR-1 | 4 | 2021 | 109 | 1.340 |
Why?
|
| Platelet Count | 8 | 2021 | 784 | 1.330 |
Why?
|
| Piperazines | 13 | 2013 | 2548 | 1.210 |
Why?
|
| CD40 Ligand | 8 | 2023 | 528 | 1.140 |
Why?
|
| Aspirin | 16 | 2018 | 3135 | 1.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 5 | 2018 | 245 | 1.020 |
Why?
|
| Anemia, Sickle Cell | 8 | 2021 | 1065 | 0.930 |
Why?
|
| Serotonin | 3 | 2024 | 1045 | 0.880 |
Why?
|
| Thrombasthenia | 6 | 2022 | 21 | 0.870 |
Why?
|
| Sudden Infant Death | 2 | 2024 | 293 | 0.860 |
Why?
|
| 14-3-3 Proteins | 1 | 2024 | 221 | 0.840 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2013 | 31 | 0.820 |
Why?
|
| Integrin beta3 | 4 | 2018 | 120 | 0.760 |
Why?
|
| Immunoglobulin Fab Fragments | 8 | 2013 | 446 | 0.730 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 440 | 0.730 |
Why?
|
| Epidermal Growth Factor | 4 | 2021 | 697 | 0.700 |
Why?
|
| Blood Coagulation | 11 | 2022 | 1163 | 0.700 |
Why?
|
| Thromboxane B2 | 4 | 2017 | 143 | 0.690 |
Why?
|
| Immunophenotyping | 6 | 2023 | 1864 | 0.680 |
Why?
|
| Electricity | 3 | 2021 | 173 | 0.680 |
Why?
|
| Platelet Membrane Glycoproteins | 16 | 2016 | 282 | 0.650 |
Why?
|
| Drug Resistance | 5 | 2009 | 1592 | 0.620 |
Why?
|
| Hematologic Agents | 1 | 2018 | 39 | 0.610 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 1172 | 0.600 |
Why?
|
| Cyclooxygenase 1 | 2 | 2009 | 98 | 0.600 |
Why?
|
| Megakaryocytes | 2 | 2022 | 557 | 0.590 |
Why?
|
| Hemorrhage | 7 | 2021 | 3464 | 0.590 |
Why?
|
| Dog Diseases | 1 | 2018 | 143 | 0.580 |
Why?
|
| Thrombopoiesis | 1 | 2018 | 160 | 0.550 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 1655 | 0.550 |
Why?
|
| Platelet Adhesiveness | 8 | 2016 | 154 | 0.550 |
Why?
|
| Cell-Derived Microparticles | 4 | 2021 | 159 | 0.500 |
Why?
|
| Acute Coronary Syndrome | 6 | 2018 | 2193 | 0.460 |
Why?
|
| Cytoplasmic Granules | 3 | 2022 | 574 | 0.420 |
Why?
|
| Adenosine | 2 | 2017 | 812 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 21 | 2013 | 9245 | 0.380 |
Why?
|
| Omeprazole | 1 | 2012 | 106 | 0.380 |
Why?
|
| Thiazoles | 1 | 2018 | 1530 | 0.370 |
Why?
|
| Humans | 127 | 2024 | 767040 | 0.350 |
Why?
|
| Leukocytes | 8 | 2016 | 2034 | 0.350 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2009 | 13 | 0.350 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 551 | 0.340 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2021 | 616 | 0.340 |
Why?
|
| Receptors, Thrombin | 4 | 2022 | 130 | 0.340 |
Why?
|
| Liver Diseases | 1 | 2018 | 1304 | 0.340 |
Why?
|
| Thrombin | 9 | 2021 | 600 | 0.330 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2023 | 131 | 0.330 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1481 | 0.320 |
Why?
|
| Pyrazoles | 5 | 2019 | 2028 | 0.300 |
Why?
|
| Microfilament Proteins | 6 | 2017 | 1130 | 0.300 |
Why?
|
| Clot Retraction | 1 | 2007 | 13 | 0.300 |
Why?
|
| Communication | 2 | 2022 | 3904 | 0.300 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 3702 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2018 | 10748 | 0.280 |
Why?
|
| Cardiology | 1 | 2018 | 1701 | 0.280 |
Why?
|
| Factor Va | 2 | 2021 | 10 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 3804 | 0.260 |
Why?
|
| Cell Adhesion Molecules | 7 | 2017 | 1612 | 0.260 |
Why?
|
| Arachidonic Acid | 3 | 2006 | 430 | 0.250 |
Why?
|
| Coronary Artery Disease | 8 | 2016 | 6573 | 0.250 |
Why?
|
| Fibrinogen | 7 | 2006 | 892 | 0.250 |
Why?
|
| Prodrugs | 1 | 2007 | 274 | 0.250 |
Why?
|
| Blood Coagulation Factors | 1 | 2007 | 371 | 0.250 |
Why?
|
| Cross-Over Studies | 6 | 2017 | 2105 | 0.240 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 246 | 0.230 |
Why?
|
| Dogs | 7 | 2018 | 3834 | 0.230 |
Why?
|
| Double-Blind Method | 12 | 2019 | 12451 | 0.220 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 597 | 0.220 |
Why?
|
| Peptides | 4 | 2013 | 4348 | 0.220 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 4247 | 0.220 |
Why?
|
| Thrombelastography | 3 | 2018 | 194 | 0.210 |
Why?
|
| Cardiovascular Diseases | 8 | 2015 | 15645 | 0.210 |
Why?
|
| Male | 58 | 2024 | 364203 | 0.210 |
Why?
|
| Female | 56 | 2024 | 396660 | 0.200 |
Why?
|
| Phosphoproteins | 5 | 2017 | 2448 | 0.200 |
Why?
|
| Benzoates | 2 | 2015 | 213 | 0.200 |
Why?
|
| Tyrosine | 3 | 2003 | 1425 | 0.200 |
Why?
|
| Hydrazines | 2 | 2015 | 223 | 0.200 |
Why?
|
| Annexin A5 | 2 | 2015 | 102 | 0.190 |
Why?
|
| Gaucher Disease | 1 | 2021 | 110 | 0.180 |
Why?
|
| Eczema | 1 | 2023 | 244 | 0.180 |
Why?
|
| Calgranulin A | 1 | 2021 | 81 | 0.180 |
Why?
|
| Kinetics | 7 | 2017 | 6287 | 0.180 |
Why?
|
| Calgranulin B | 1 | 2021 | 87 | 0.180 |
Why?
|
| Monocytes | 6 | 2015 | 2598 | 0.180 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 456 | 0.170 |
Why?
|
| NFATC Transcription Factors | 1 | 2022 | 393 | 0.170 |
Why?
|
| Electric Stimulation | 2 | 2015 | 1736 | 0.170 |
Why?
|
| Middle Aged | 40 | 2021 | 223233 | 0.160 |
Why?
|
| Fibrinolytic Agents | 4 | 2016 | 2079 | 0.160 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2018 | 50 | 0.160 |
Why?
|
| Phenotype | 7 | 2023 | 16718 | 0.160 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2018 | 51 | 0.150 |
Why?
|
| Case-Control Studies | 10 | 2018 | 22254 | 0.150 |
Why?
|
| Cattle | 7 | 2019 | 3813 | 0.150 |
Why?
|
| Adenosine Monophosphate | 2 | 2017 | 232 | 0.150 |
Why?
|
| Hypothermia, Induced | 1 | 2003 | 754 | 0.150 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 396 | 0.150 |
Why?
|
| Area Under Curve | 2 | 2013 | 1639 | 0.150 |
Why?
|
| Phosphatidylserines | 3 | 2021 | 186 | 0.150 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 91 | 0.150 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 213 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2013 | 1419 | 0.150 |
Why?
|
| Thrombosis | 6 | 2024 | 2954 | 0.140 |
Why?
|
| Hemophilia A | 1 | 2021 | 359 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 197 | 0.140 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 6310 | 0.140 |
Why?
|
| Calpain | 1 | 2017 | 146 | 0.140 |
Why?
|
| Asphyxia | 1 | 2017 | 60 | 0.140 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 685 | 0.130 |
Why?
|
| Adult | 32 | 2021 | 223317 | 0.130 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 238 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 385 | 0.130 |
Why?
|
| Receptors, Purinergic P2X1 | 1 | 2015 | 8 | 0.130 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2015 | 24 | 0.130 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 974 | 0.130 |
Why?
|
| Octoxynol | 1 | 2015 | 76 | 0.130 |
Why?
|
| Drug Stability | 1 | 2015 | 289 | 0.120 |
Why?
|
| Cell Adhesion | 5 | 2003 | 3093 | 0.120 |
Why?
|
| Antibodies | 2 | 2023 | 2419 | 0.120 |
Why?
|
| Gastroparesis | 1 | 2017 | 143 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2021 | 1531 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4855 | 0.120 |
Why?
|
| Factor V | 2 | 2008 | 168 | 0.120 |
Why?
|
| Integrins | 4 | 1993 | 840 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2010 | 1721 | 0.110 |
Why?
|
| Collagen | 5 | 2009 | 2636 | 0.110 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 486 | 0.110 |
Why?
|
| Drug Monitoring | 3 | 2021 | 963 | 0.110 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 409 | 0.110 |
Why?
|
| Stereoisomerism | 1 | 2014 | 612 | 0.110 |
Why?
|
| Time Factors | 9 | 2018 | 40154 | 0.100 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 64 | 0.100 |
Why?
|
| Methionine | 2 | 1986 | 570 | 0.100 |
Why?
|
| Pain | 2 | 2021 | 5101 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2013 | 1399 | 0.100 |
Why?
|
| Reference Values | 2 | 2012 | 4918 | 0.100 |
Why?
|
| Peptide Fragments | 7 | 2015 | 5141 | 0.100 |
Why?
|
| Cell Line | 3 | 2016 | 15567 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 426 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 12250 | 0.100 |
Why?
|
| International Cooperation | 1 | 2018 | 1434 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2019 | 65295 | 0.100 |
Why?
|
| Light | 2 | 2015 | 1358 | 0.100 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 3052 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 996 | 0.090 |
Why?
|
| Consensus | 1 | 2021 | 3207 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10455 | 0.090 |
Why?
|
| Infant | 4 | 2024 | 36485 | 0.090 |
Why?
|
| Young Adult | 13 | 2021 | 59980 | 0.090 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2015 | 386 | 0.090 |
Why?
|
| Thromboxane A2 | 2 | 2008 | 87 | 0.090 |
Why?
|
| Vascular Patency | 3 | 2009 | 915 | 0.090 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 142 | 0.090 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 221 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 1794 | 0.090 |
Why?
|
| Neutrophils | 5 | 2022 | 3779 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 1331 | 0.090 |
Why?
|
| Animals | 27 | 2022 | 168965 | 0.090 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2009 | 9 | 0.090 |
Why?
|
| Diabetic Angiopathies | 2 | 2016 | 806 | 0.090 |
Why?
|
| Adolescent | 11 | 2021 | 89046 | 0.090 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2009 | 25 | 0.080 |
Why?
|
| Drug Substitution | 1 | 2012 | 292 | 0.080 |
Why?
|
| Parathyroid Hormone | 3 | 1986 | 1804 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 2009 | 146 | 0.080 |
Why?
|
| Aged | 18 | 2019 | 171319 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 1197 | 0.080 |
Why?
|
| Hydroxyurea | 2 | 2021 | 284 | 0.080 |
Why?
|
| Thromboplastin | 2 | 2007 | 289 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4424 | 0.080 |
Why?
|
| Cell Separation | 2 | 2005 | 1717 | 0.080 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 301 | 0.070 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2007 | 14 | 0.070 |
Why?
|
| Biotransformation | 1 | 2007 | 165 | 0.070 |
Why?
|
| ROC Curve | 1 | 2015 | 3618 | 0.070 |
Why?
|
| Sepsis | 1 | 2022 | 2605 | 0.070 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 15424 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 20169 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3511 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2019 | 3044 | 0.070 |
Why?
|
| Calcium | 4 | 2021 | 5792 | 0.070 |
Why?
|
| Chest Pain | 1 | 2014 | 1101 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2013 | 8310 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 616 | 0.070 |
Why?
|
| Epitopes | 5 | 1992 | 2526 | 0.070 |
Why?
|
| Receptors, Peptide | 1 | 1988 | 280 | 0.070 |
Why?
|
| Infant, Newborn | 4 | 2024 | 26396 | 0.070 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2007 | 453 | 0.070 |
Why?
|
| Glycoproteins | 4 | 2002 | 2200 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 26325 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 361 | 0.070 |
Why?
|
| Cystic Fibrosis | 2 | 2007 | 1292 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 3408 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2015 | 11657 | 0.070 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2006 | 69 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 3626 | 0.070 |
Why?
|
| Morpholines | 1 | 2009 | 584 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2920 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2018 | 3964 | 0.070 |
Why?
|
| Oligopeptides | 5 | 1993 | 1195 | 0.060 |
Why?
|
| Withholding Treatment | 1 | 2010 | 619 | 0.060 |
Why?
|
| Receptors, Immunologic | 2 | 1989 | 1418 | 0.060 |
Why?
|
| Antigens, Surface | 2 | 1986 | 1617 | 0.060 |
Why?
|
| Dalteparin | 2 | 2003 | 44 | 0.060 |
Why?
|
| Blood Cells | 1 | 2007 | 309 | 0.060 |
Why?
|
| Cell Communication | 3 | 2022 | 1660 | 0.060 |
Why?
|
| Wound Healing | 1 | 2016 | 2800 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5716 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 42606 | 0.060 |
Why?
|
| Protein Conformation | 5 | 2001 | 3948 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 3449 | 0.060 |
Why?
|
| Heterozygote | 2 | 2011 | 2794 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2018 | 4854 | 0.060 |
Why?
|
| Benzamides | 1 | 2009 | 1376 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2015 | 4525 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2018 | 6611 | 0.060 |
Why?
|
| Binding, Competitive | 4 | 2001 | 1141 | 0.050 |
Why?
|
| Crotalid Venoms | 2 | 1993 | 29 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2018 | 9362 | 0.050 |
Why?
|
| Tissue Fixation | 2 | 2001 | 245 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2015 | 9660 | 0.050 |
Why?
|
| Laboratories | 1 | 2007 | 463 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2015 | 3698 | 0.050 |
Why?
|
| Endothelium | 2 | 2003 | 768 | 0.050 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2006 | 483 | 0.050 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2023 | 163 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2006 | 433 | 0.050 |
Why?
|
| Amino Acid Sequence | 11 | 1992 | 13411 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2013 | 2697 | 0.050 |
Why?
|
| Gene Expression | 1 | 2015 | 7587 | 0.050 |
Why?
|
| Genotype | 5 | 2017 | 13035 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2017 | 23621 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 11513 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1907 | 0.050 |
Why?
|
| Protein Binding | 3 | 2002 | 9327 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2001 | 51 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3599 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1854 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 978 | 0.050 |
Why?
|
| Antisickling Agents | 1 | 2021 | 72 | 0.050 |
Why?
|
| Comorbidity | 1 | 2015 | 10582 | 0.050 |
Why?
|
| Coronary Disease | 3 | 2005 | 5914 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 1984 | 740 | 0.040 |
Why?
|
| Hirudins | 1 | 2001 | 179 | 0.040 |
Why?
|
| Child | 4 | 2018 | 80771 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2021 | 404 | 0.040 |
Why?
|
| Hemostatics | 1 | 2003 | 247 | 0.040 |
Why?
|
| Rats | 3 | 2015 | 23713 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 2591 | 0.040 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 18330 | 0.040 |
Why?
|
| Hypertension | 1 | 2019 | 8615 | 0.040 |
Why?
|
| Inflammation | 5 | 2022 | 10869 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6513 | 0.040 |
Why?
|
| Factor VIII | 1 | 2021 | 349 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 2054 | 0.040 |
Why?
|
| Heparin | 3 | 2003 | 1636 | 0.040 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 1217 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2003 | 893 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 1531 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2353 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2007 | 4143 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 1759 | 0.040 |
Why?
|
| Epinephrine | 3 | 2008 | 782 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2012 | 682 | 0.040 |
Why?
|
| Calcitonin | 4 | 1980 | 328 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1897 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 94 | 0.040 |
Why?
|
| Recurrence | 2 | 2009 | 8504 | 0.040 |
Why?
|
| Dosage Forms | 1 | 2017 | 55 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 2495 | 0.030 |
Why?
|
| Risk Factors | 4 | 2018 | 74886 | 0.030 |
Why?
|
| Actigraphy | 1 | 2021 | 527 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1733 | 0.030 |
Why?
|
| Molecular Sequence Data | 9 | 1992 | 17608 | 0.030 |
Why?
|
| Ligands | 4 | 1991 | 3273 | 0.030 |
Why?
|
| Binding Sites | 6 | 1993 | 6014 | 0.030 |
Why?
|
| E-Selectin | 1 | 2018 | 576 | 0.030 |
Why?
|
| Smoking | 2 | 2013 | 9081 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2014 | 54886 | 0.030 |
Why?
|
| Biological Availability | 1 | 2017 | 387 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 826 | 0.030 |
Why?
|
| Cell Division | 2 | 2003 | 4473 | 0.030 |
Why?
|
| Paresis | 1 | 2017 | 177 | 0.030 |
Why?
|
| Edetic Acid | 2 | 2004 | 277 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1998 | 272 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2017 | 326 | 0.030 |
Why?
|
| Chromatography, Affinity | 3 | 1992 | 524 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 1969 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2000 | 7868 | 0.030 |
Why?
|
| Heredity | 1 | 2015 | 149 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 7871 | 0.030 |
Why?
|
| Placebos | 1 | 2018 | 1660 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 159 | 0.030 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1993 | 49 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2007 | 18989 | 0.030 |
Why?
|
| Exocytosis | 1 | 2015 | 323 | 0.030 |
Why?
|
| Fibrin | 1 | 2016 | 514 | 0.030 |
Why?
|
| Autopsy | 1 | 2017 | 1011 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14672 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 1321 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1587 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8732 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12069 | 0.030 |
Why?
|
| Coronary Circulation | 2 | 2009 | 1603 | 0.020 |
Why?
|
| Brain Stem | 1 | 2017 | 858 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 1991 | 136 | 0.020 |
Why?
|
| Erythroid Cells | 1 | 2013 | 237 | 0.020 |
Why?
|
| Carbazoles | 1 | 2013 | 230 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2011 | 83 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 1673 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2001 | 4032 | 0.020 |
Why?
|
| Cell Shape | 1 | 2011 | 372 | 0.020 |
Why?
|
| United States | 1 | 2018 | 72971 | 0.020 |
Why?
|
| Cell Membrane | 5 | 2005 | 3642 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2009 | 11 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 561 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2009 | 64 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 622 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1606 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 638 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 6067 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 1990 | 269 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 1986 | 2221 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 1743 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 13085 | 0.020 |
Why?
|
| Behavior | 1 | 2011 | 538 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 1168 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15925 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 167 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 84 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1990 | 512 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 780 | 0.020 |
Why?
|
| Temperature | 2 | 2011 | 2232 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1990 | 1062 | 0.020 |
Why?
|
| Extracellular Space | 2 | 1986 | 563 | 0.020 |
Why?
|
| Fibronectins | 1 | 1991 | 722 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 878 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 683 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2007 | 95 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 776 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1990 | 350 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 3108 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1774 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2016 | 2387 | 0.020 |
Why?
|
| Mice | 3 | 2022 | 81912 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 1995 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2270 | 0.020 |
Why?
|
| Methanol | 1 | 1986 | 91 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2005 | 238 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2850 | 0.020 |
Why?
|
| Blotting, Western | 3 | 2005 | 5022 | 0.020 |
Why?
|
| Cytoplasm | 2 | 1986 | 1504 | 0.020 |
Why?
|
| Insulin | 1 | 2019 | 6602 | 0.020 |
Why?
|
| Alprostadil | 1 | 2005 | 86 | 0.020 |
Why?
|
| Alleles | 2 | 2013 | 6893 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 2005 | 286 | 0.010 |
Why?
|
| Destrin | 1 | 2004 | 10 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3431 | 0.010 |
Why?
|
| Cyanogen Bromide | 1 | 1984 | 75 | 0.010 |
Why?
|
| Cysteamine | 1 | 1984 | 24 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 8108 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1986 | 973 | 0.010 |
Why?
|
| Factor Xa | 1 | 2005 | 165 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2004 | 91 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 14766 | 0.010 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2004 | 42 | 0.010 |
Why?
|
| Amino Acids | 2 | 1992 | 1712 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2011 | 1361 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 109 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2013 | 2575 | 0.010 |
Why?
|
| Polysomnography | 1 | 2011 | 1868 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 2011 | 839 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2592 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3582 | 0.010 |
Why?
|
| Ibuprofen | 1 | 2005 | 228 | 0.010 |
Why?
|
| Species Specificity | 1 | 2007 | 2412 | 0.010 |
Why?
|
| Methods | 1 | 2003 | 1065 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 1374 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 384 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 1078 | 0.010 |
Why?
|
| Dipeptides | 1 | 2004 | 386 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14476 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 39317 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 2394 | 0.010 |
Why?
|
| Atherectomy | 1 | 2001 | 41 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 1981 | 167 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 391 | 0.010 |
Why?
|
| Kidney | 2 | 2010 | 7063 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 10393 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1882 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1986 | 2478 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2001 | 202 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2227 | 0.010 |
Why?
|
| Platelet Storage Pool Deficiency | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1472 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 750 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 250 | 0.010 |
Why?
|
| Blood | 1 | 2003 | 596 | 0.010 |
Why?
|
| Vitamin E | 1 | 2005 | 872 | 0.010 |
Why?
|
| Genome, Human | 1 | 2013 | 4441 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 2003 | 519 | 0.010 |
Why?
|
| Models, Biological | 1 | 2016 | 9464 | 0.010 |
Why?
|
| Blood Banks | 1 | 2000 | 107 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2001 | 683 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 24299 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2009 | 4186 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22361 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1984 | 3587 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 3271 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2227 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1981 | 762 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4572 | 0.010 |
Why?
|
| Calibration | 1 | 2000 | 817 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 835 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 706 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9513 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1806 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 1688 | 0.010 |
Why?
|
| Mutation | 2 | 1992 | 30211 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2011 | 4526 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8531 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8535 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12823 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1979 | 2012 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2006 | 3114 | 0.010 |
Why?
|
| Base Sequence | 3 | 1992 | 12414 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 2086 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 5954 | 0.010 |
Why?
|
| Radioimmunoassay | 3 | 1980 | 861 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 41718 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7236 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 13048 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 18063 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4349 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13646 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1992 | 6507 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 29963 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18401 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1991 | 645 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 416 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 12793 | 0.010 |
Why?
|
| Vitronectin | 1 | 1989 | 40 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11063 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1057 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 1989 | 48 | 0.010 |
Why?
|
| CHO Cells | 1 | 1992 | 1376 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 1729 | 0.000 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 208 | 0.000 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 1677 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 2472 | 0.000 |
Why?
|
| Cricetinae | 1 | 1992 | 2415 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1989 | 816 | 0.000 |
Why?
|
| Aspartic Acid | 1 | 1990 | 575 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1990 | 1430 | 0.000 |
Why?
|
| Brain Ischemia | 1 | 2000 | 3001 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1989 | 2168 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 59548 | 0.000 |
Why?
|
| DNA | 2 | 1992 | 7210 | 0.000 |
Why?
|
| Thyroid Neoplasms | 1 | 1979 | 2355 | 0.000 |
Why?
|
| Sialoglycoproteins | 1 | 1986 | 316 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1993 | 2628 | 0.000 |
Why?
|
| Lung Neoplasms | 2 | 1980 | 13491 | 0.000 |
Why?
|
| Pancreas | 1 | 1991 | 1699 | 0.000 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 4114 | 0.000 |
Why?
|
| RNA | 1 | 1992 | 2715 | 0.000 |
Why?
|
| Radioligand Assay | 1 | 1980 | 365 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1987 | 3738 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1979 | 634 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1979 | 2078 | 0.000 |
Why?
|
| Carcinoma | 2 | 1980 | 2326 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1981 | 1750 | 0.000 |
Why?
|
| Parathyroid Glands | 1 | 1978 | 522 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1979 | 419 | 0.000 |
Why?
|
| Biological Assay | 1 | 1978 | 626 | 0.000 |
Why?
|
| Retina | 1 | 1986 | 2659 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1979 | 1228 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1980 | 4049 | 0.000 |
Why?
|
| Thyroidectomy | 1 | 1978 | 912 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1979 | 1441 | 0.000 |
Why?
|
| Adenocarcinoma | 2 | 1980 | 6360 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1979 | 4838 | 0.000 |
Why?
|
| Sex Factors | 1 | 1978 | 10622 | 0.000 |
Why?
|
| Aging | 1 | 1978 | 8729 | 0.000 |
Why?
|